Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyper-CVAD chemoimmunotherapy with or without rituximab for B-cell acute lymphoblastic leukemia
IRCT20140519017756N35Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of rituximab in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Mashhad University of Medical Sciences. Started Jan 2018; status: completed.
02
Drugs
rituximab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on IRCT20140519017756N35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140519017756N35.